4-(4-methylcyclohexyl)-4-oxobutyric acid

structure in first source

Also Known As:

4-(trans-4-methylcyclohexyl)-4-oxobutanoic acid; JTT 608; JTT-608

Networked: 7 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 6
        Cyclohexanes: 3
        4-(4-methylcyclohexyl)-4-oxobutyric acid: 7
- Carboxylic Acids: 973
  - Acyclic Acids
    - Butyrates: 2613
      - 4-(4-methylcyclohexyl)-4-oxobutyric acid: 7
Lipids: 114793
- Fatty Acids: 27405
  - Volatile Fatty Acids: 3052
    - Butyrates: 2613
      - 4-(4-methylcyclohexyl)-4-oxobutyric acid: 7

Experts

1.	Ohta, T: 2 articles (09/2005 - 06/2001)
2.	Furukawa, N: 1 article (09/2005)
3.	Matsui, K: 1 article (09/2005)
4.	Matsushita, M: 1 article (09/2005)
5.	Miyajima, K: 1 article (09/2005)
6.	Sasase, T: 1 article (09/2005)
7.	Yonemori, F: 1 article (09/2005)
8.	Furukawa, Noboru: 1 article (08/2003)
9.	Komuro, Goro: 1 article (08/2003)
10.	Miyajima, Katsuhiro: 1 article (08/2003)

Related Diseases

1.	Diabetes Complications 09/01/2005 - "In examination of other diabetic complications, JTT-608 ameliorated the reduced motor nerve conduction velocities observed in diabetic rats and inhibited the incidence of cataracts with diabetes. " 09/01/2005 - "We conclude that a newly developed antidiabetic agent, JTT-608, improves the pancreatic function and prevents the development of diabetic complications by inhibition of daily postprandial hyperglycaemia and could be useful for the treatment of diabetic subjects with impaired insulin secretion." 09/01/2005 - "Haemoglobin A1C (HbA1C) and fasting blood glucose levels were measured at 4-week intervals, and effects of JTT-608 on pancreatic function and diabetic complications were examined after dosing period. "
2.	Glucose Intolerance 09/01/2005 - "After the treatment period of 12 weeks, JTT-608 further improved the early insulin secretion and the impaired glucose tolerance after meal loading in the diabetic rats. "
3.	Type 2 Diabetes Mellitus (MODY) 06/01/2001 - "The present findings indicate that JTT-608 is a more useful new class of therapeutic drug for patients with non-insulin-dependent diabetes mellitus, compared with sulfonylurea derivatives." 04/23/1999 - "In isolated, perfused pancreas of neonatally streptozotocin-induced non-insulin-dependent diabetes mellitus rats (nSTZ rats), JTT-608 (200 microM) normalized the first phase and doubled the second phase of insulin secretion. " 04/01/1999 - "1. We investigated the pharmacological effects of a new antidiabetic agent, JTT-608, in comparison with the sulphonylurea tolbutamide, in Goto-Kakizaki (GK) rats, a genetic model of non-obese insulin-dependent diabetes mellitus (NIDDM). "
4.	Insulinoma 04/23/1999 - "The effects of JTT-608 [trans-4-(4-methylcyclohexyl)-4-oxobutyric acid], a novel antidiabetic compound, on insulin secretion were investigated using mouse insulinoma cell line (MIN6 cells) and isolated, perfused rat pancreas. "
5.	Hypoglycemia (Reactive Hypoglycemia) 01/01/2001 - "A new nonsulfonylurea oral hypoglycemic agent, JTT-608, has been reported to stimulate insulin release at elevated, but not low, glucose concentrations and consequently not to induce hypoglycemia in rats. "

Related Drugs and Biologics

1.	Hypoglycemic Agents (Hypoglycemics)
2.	Glucose (Dextrose)
3.	Blood Glucose (Blood Sugar)
4.	Tolbutamide (Orinase)
5.	Streptozocin (Streptozotocin)
6.	Insulin (Novolin)
7.	Acids

Related Therapies and Procedures

1.	Glycemic Control